111 related articles for article (PubMed ID: 2650302)
1. The effects of OKT3 anti-rejection therapy on in situ allograft infiltrating lymphocytes.
Kerr PG; Atkins RC
Transplant Proc; 1989 Feb; 21(1 Pt 1):977-8. PubMed ID: 2650302
[No Abstract] [Full Text] [Related]
2. Anti-T12 monoclonal antibody therapy of acute renal allograft rejection.
Milford EL; Carpenter CB; Kirkman RL; Tilney NL; Mazoujian G; Strom TB; Lazarus JM; Schlossman SF; Guttmann RD; Lowry R
Transplant Proc; 1987 Feb; 19(1 Pt 3):1910. PubMed ID: 3274450
[No Abstract] [Full Text] [Related]
3. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.
Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U
Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454
[No Abstract] [Full Text] [Related]
4. New insights into therapy with monoclonal antibodies in allograft transplantation.
Schena FP
Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
[No Abstract] [Full Text] [Related]
5. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody.
Waid TH; Lucas BA; Thompson JS; Brown S; Moore D; Amlot P; Janossy G
Transplant Proc; 1989 Feb; 21(1 Pt 2):1778-84. PubMed ID: 2652582
[No Abstract] [Full Text] [Related]
6. Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation.
Birkeland SA; Svendsen V; Rohr N; Hansen BL; Elbirk A; Foged N; Køhler F
Transplant Proc; 1988 Jun; 20(3):451-4. PubMed ID: 3289183
[No Abstract] [Full Text] [Related]
7. Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients--CD4+ T cells play an essential role in the rejection process.
Reinke P; Kern F; Fietze E; Döcke WD; Ewert R; Emmrich F; Volk HD
Transplant Proc; 1995 Feb; 27(1):859-62. PubMed ID: 7879207
[No Abstract] [Full Text] [Related]
8. Regulation of human allograft rejection: kidney-infiltrating suppressor inducer and suppressor effector T-cells are reduced during rejection.
Tötterman TH; Hanås E; Larsson E; Sjöberg O; Tufveson G
Transplant Proc; 1989 Feb; 21(1 Pt 1):359-60. PubMed ID: 2523133
[No Abstract] [Full Text] [Related]
9. OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.
Goldstein G; Norman DJ; Shield CF; Kreis H; Burdick J; Flye MW; Rivolta E; Starzl T; Monaco A
Prog Clin Biol Res; 1986; 224():239-49. PubMed ID: 3540993
[No Abstract] [Full Text] [Related]
10. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
Chatenoud L; Bach JF
Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
[TBL] [Abstract][Full Text] [Related]
11. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
[No Abstract] [Full Text] [Related]
12. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
[No Abstract] [Full Text] [Related]
13. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
14. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine.
Thistlethwaite JR; Haag BW; Gaber AO; Stuart JK; Aronson AJ; Mayes JT; Lloyd DM; Stuart FP
Transplant Proc; 1987 Feb; 19(1 Pt 3):1901-4. PubMed ID: 3103294
[No Abstract] [Full Text] [Related]
15. The use of OKT3 for stubborn heart allograft rejection: an advance in clinical immunotherapy?
Sweeney MS; Sinnott JT; Cullison JP; Weinstein SS
J Heart Transplant; 1987; 6(6):324-8. PubMed ID: 3320302
[TBL] [Abstract][Full Text] [Related]
16. OKT3-treated kidney transplant patients: monitoring of effects on peripheral blood mononuclear cells by using two-color flow cytometry.
Harford AM; Shopp GM; Ashmore LM; Seppelt JE; Mosdell DM; Gibel LJ; Sterling WA
Transplant Proc; 1988 Feb; 20(1 Suppl 1):245-8. PubMed ID: 3279615
[No Abstract] [Full Text] [Related]
17. Use of Orthoclone OKT3 as treatment of acute renal allograft rejection and as first-line therapy in kidney transplantation.
Winde G; Dietl KH; Raidt H; Buchholz B; Lison AE; Bünte H
Transplant Proc; 1988 Oct; 20(5 Suppl 6):87-9. PubMed ID: 3140453
[No Abstract] [Full Text] [Related]
18. Phenotypic and functional analysis of kidney infiltrating T cells escaping monoclonal antibody treatment in primate renal transplantation.
Nocera A; Cosimi AB; Colvin RB; Gesner ML; Fuller TC
Transplant Proc; 1988 Apr; 20(2):205-6. PubMed ID: 3129830
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies for kidney allograft rejection.
Med Lett Drugs Ther; 1986 Oct; 28(724):97-8. PubMed ID: 3531791
[No Abstract] [Full Text] [Related]
20. CD4 monoclonal antibodies in the preclinical dog renal allograft model.
Watson CJ; Davies HS; Metcalfe SM; Cobbold SP; Rebello PR; Collier DS; Waldmann H; Calne RY
Transplant Proc; 1993 Feb; 25(1 Pt 1):804-6. PubMed ID: 8438491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
